CAMBRIDGE, Mass., Nov. 3, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced that preliminary data from its Phase 1 clinical trial evaluating BLU-285 for the treatment of advanced systemic mastocytosis (SM) will be presented in an oral presentation at the 2016 American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, December 3-6, 2016. In addition, an abstract detailing SM patients' experiences with Mast Cell Connect, the first patient-reported registry for mastocytosis, and an abstract submitted by Blueprint Medicines' collaborator Dr. Andreas Reiter from the Department of Hematology and Oncology at the University Medical Centre Mannheim, Germany, detailing preclinical data on the inhibitory effects of BLU-285 on cells derived from patients with advanced SM, have been accepted for presentation at ASH.
The accepted abstracts are listed below and are now available online on the ASH conference website: http://www.hematology.org/Annual-Meeting/. Oral Presentation: Date & Time: Sunday, December 4, 2016 at 5:00 p.m. PT ( 8:00 p.m. ET) Presentation Title: Preliminary Safety and Activity in a Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM) Session Title: 634. Myeloproliferative Syndromes: Clinical: Clinical Trials with Agents Other Than JAK Inhibitors Abstract Number: 477 Location: Marriot Marquis San Diego Marina, Marriott Grand Ballroom Salons 8-9